Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive radiotherapy following EP regimen plus HLX10 for extensive-stage small cell lung cancer
ChiCTR2500108521Phase 2Not yet recruiting
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab in small cell lung cancer (SCLC) (4 arms), sponsored by General Hospital of Ningxia Medical University. Primary endpoint: Progression-free survival (PFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500108521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108521.